Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If he gets this back over $26, he can be the new Messiah.
James, you should hold a stock because you understand a stock and think it is a good investment. Not because there is someone on board that you think is a Jesus. He is not a Jesus and you should not be his disciple. Either you believe in the company management or you don't.
I think fly is trying to tell you it is going to be back in the 20s very soon.
That is the kind of discussion that I like. Out with the weak hands so that this can move higher.
Wasn't that said before the actual expert testimony?
what do you think we have been talking about. It is on Express Scripts Preventive drug list as an example. https://www.express-scripts.com/art/open_enrollment/PDL4833D.pdf
Keep in mind there is only one Vascepa. Statins are going to be given inconsistent treatment because there are several of them. That should not be the case with V. It will take time for V to trickle through the various formularies but it will happen and the people on this board can help by contacting their pharmacy benefits administrators/insurance companies/employers to try to resolve issues. We know the drug and its benefits as well as anyone.
Yes, and if you health plan does not consider it preventative you should push back on that.
You should send them links to other pharmaceutical companies websites where they do the same thing. Oh, no, that's not possible because pharmaceuticals companies don't do that.
Amarin is not looking to settle. The trial went in Amarin's favor and they are planning on winning.
I'm experienced and I am not frustrated.
You do realize they would still have the same market cap.
I am just glad they went with the American Diabetes Association and went down to 135. Between the American Diabetes Association and now the American Association of Clinical Endocrinologist this should secure the endocrinologist population. I think the AACE is really the larger organization and their guidelines are what most endocrinologist actually use.
New AACE algorithm with Icosapent Ethyl recommendation. Triglycerides 135-499
https://www.aace.com/pdfs/diabetes/algorithm-exec-summary.pdf
State Medicaid plans are still only paying for Generic Lovaza. It will take time for Amarin to get to each state.
Any press is good press when you are trying to educate the public on a drug.
When the market turns people are going to be looking for companies that are growing revenue 80+% YOY.
Why would you settle when Dr. Reddy does not have a case or even competent expert witnesses?
If you don't get formularies adjusted for new indications before you start DTC ads, physicians will not be happy.
Ranjo, Amarin already has a sales team and already has sales. I know people come here and have no idea what they are talking about so I just thought I would check in with you since they are not creating sales organization from scratch as you state.
Yes, they sold a portion.
DTC comes in many ways. Here is a new post on twitter from just an hour ago.
https://diabetessisters.org/newsletter/february-2020-partner-spotlight-amarin
DiabetesSisters
@diabetessisters
·
1h
VASCEPA is now approved, along with certain meds, to reduce risk of heart attack, stroke & certain heart issues requiring hospitalization in adults w/ heart disease or diabetes & 2 or more risk factors. Learn more from
@Amarincorp
in our Partner Spotlight http://ow.ly/U20L50yaAiU
These are the annual option awards, basically their bonuses, part of their salary
Did you get an email today? It looks like DTC has begun. vascepainformation@vascepa.com
Form 4's are out.
Reduce it USA results have been published in Circulation. February 4, 2020 Vol 141, Issue 5 https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044440#.Xjn0Sd6Hvc8.twitter
I really don't know much about Tesla but don't they own a Solar company?
I hope you got out right after you typed this.
Have you been drinking again?
High deductible plans are required by law to have essential drug list. Vascepa should be on it. If it is not, call your plan and ask why not.
Yes, shorts are having a little fun but that will not continue. Value of the company continues to grow.
Is Vascepa on your Essential drug list? If it is not, you should ask that it be added.
You know what they say about people who assume.
Just curious, who is going to have a cardiovascular outcomes trial finished in 5 years?
Dr Bhatt speaks on twitter
Replying to
@omega360
@pabeda1
and 14 others
The effect of icosapent ethyl on various inflammatory markers is interesting, including dose-related effects. Really does support pleiotropic effects of the 4 grams a day that was found to be so effective in REDUCE-IT.
Points to other things in the thread.
https://academic.oup.com/clinchem/article/62/4/593/5611758
https://www.sciencedirect.com/science/article/pii/S0021915016312540
also,
K Trivedi
@omega360
Replying to
@SABOURETCardio
@pabeda1
and 13 others
Looking fwd to Dr. Nordestgaard’s upcoming publication on Remnant Cholesterol (RC). He showed a slide at AHA as coming attractions ?? Keep a close eye on RC. Separately, I’m curious if RC assoc w/ EPA levels...implications for alzheimer’s, cancer, infectious dz susceptibility..
I can't see how the ads can be a waste of money when physicians and potential patients are seeing the ad. The ads weren't a waste of money prior to the expanded approval so why would they be a waste of money now.
The thing is with this GIA, we already have growing sales that are already at a considerable run rate. With most GIA scenarios, including AMRN back in 2012, sales start at zero.
Back in 2012, when AMRN announced going it alone, it was time to sell the stock. Not the case now. Market cap is at 6.5B now because they are succeeding. Now it is about showing the sales moving forward.
This is the last chance for shorts to play around with this. Scripts will start moving higher again next week, earnings later this month, patent settlement in March will all cause this stock to move higher.
No Florida state taxes on distributions, capital gains or dividends.
I'll do it. Shorts are sensing this is their last chance to get out of Amarin. Time for them to cover their 42 Million short shares. It should be epic. Don't be the last to cover you're short.